NEW YORK (GenomeWeb) – Illumina said today that it is partnering with Merck Serono, the biopharmaceuticals business of Germany's Merck, to develop a universal oncology diagnostic that uses next-generation sequencing.

The collaboration adds to a similar agreement Illumina struck with AstraZeneca, Janssen Biotech, and Sanofi last year to develop a universal test system for clinical trials of targeted cancer therapies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.